IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

ISSN
0975-2366
5 - Years Impact Factor

Year 2012 - 2016

Impact Factor: 1.55

Total Publications: 317

Total Citation: 491

Year 2011 - 2015

Impact Factor: 1.46

Total Publications: 326

Total Citation: 477

Year 2010 - 2014

Impact Factor: 1.3

Total Publications: 313

Total Citation: 407

Year 2009 - 2013

Impact Factor: 0.973

Total Publications: 293

Total Citation: 285

Current Issue
22nd NATIONAL CONVENTION

22nd National Convention of Society of Pharmacognosy & International Conference. For more details visit


For More Detail Visit ncsp.ganpatuniversity.ac.in
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPRT ISSUE

January - March 6 [1] 2014

Click to download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Less Toxic Nanoparticles Of Platinum Compound For The Treatment Of Cancer

Author: MS. DEVA, DR. SHOBHNA SINGH, DR. M.M. ABDULLAHA
Abstract: The objective of this research was dose reduction and toxicity reduction. Dose reduction: various anti-cancer drugs are very costly and their high dose increases cost. If bioavailability is enhanced, the dose shall be reduced thereby the cost will also decrease. Dose reduction will also reduce toxicity and the preparation will become more tolerable. In this study the nanoparticles were developed by using modified method with the drug cisplatin which was later evaluated for stability, toxicity and therapeutic efficacy using various in-vitro and in-vivo techniques like SRB assay. The resulting dosage form found to be more effected and less toxic then the marketed preparation of drug cisplatin which is an i.v. injection. As cisplatin is a platinum compound and has the biggest drawback of the toxic side effects, which is making the chemotherapy less acceptable but with preparation of nanoparticles side effects were minimized without harming the therapeutic efficacy. Anti-cancer agents, have a number of adverse side effects and high levels of toxicity e.g. Hair loss due to the effects on hair follicles, anaemia, immune system impairment, and clotting problems, reduction in the number of red cells, white cells, and platelets. The nanoparticles were prepared using new generation polymer namely EUDRAGIT. The method was self modified for the preparation of these nanoparticles. Process optimization and validation was done before the final nanoparticles were obtained. The nanoparticles obtained were smooth and almost round as elicited by SEM and stable more than a year as concluded from stabilities studies.
Keyword: Eudragit, Nanoparticles, anti cancer, cisplatin, chemotherapy.
DOI: https://doi.org/10.31838/ijpr/2019.11.02.003
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
Pharmacovigilance: Current Scenario and Emerging Trends

National Conference sponsored by GUJCOST on 03.08.2019 at SNLPCP, Umrakh

Download Brochure
News & Events
0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free
0.07
2017CiteScore
 
11th percentile
Powered by  Scopus
Impact Factor for five years is 1.55 (2012 - 2016)

Year 2011 - 2015 Impact Factor - 1.46 Total Publications - 326 Total Citations - 477